Search Results

You are looking at 191 - 200 of 452 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani

are perhaps most intriguing, 61 which randomized 1059 patients with stage II or III gastric cancer who underwent D2 surgical resection to either observation or 1 year of oral S-1 adjuvant therapy. S-1 is an orally active combination of tegafur (i

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Thus, in these high-risk patients, offering SLNB would seem reasonable to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. The significance of tumor regression is debatable, with more recent

Full access

Christopher G. Willett

. Locoregional Rectal Cancer: What's New “The rectal cancer guidelines have been completely reworked to include the idea of mirroring the adjuvant therapies that we use in colon cancer,” said Dr. Grothey. “In the past few years, every time our committee looked

Full access

Ingrid A. Mayer

by progressive disease within 6 months of starting treatment with endocrine therapy in the metastatic setting, or the development of metastatic recurrence during or shortly after completing adjuvant therapy. Secondary (acquired) resistance is

Full access

J. Sybil Biermann

extremity: a review of 349 cases from a single institution . Cancer Treat Rev 2010 ; 36 : 1 – 7 . 2. Becker WT Dohle J Bernd L . Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy . J

Full access

Eric Jonasch

is partial or radical nephrectomy or, in select patients, active surveillance. Further treatment is typically not recommended. “Following nephrectomy, adjuvant therapy for RCC has been an exercise in frustration,” he pointed out. Recent studies

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

Pritchard KI Paterson AHG Fine S . Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor

Full access

the latest updates to the Pancreatic Guideline and provided his perspective regarding adjuvant therapy in pancreatic disease. NCCN Breast Cancer Panel Chair Dr. Robert Carlson provided the NCCN Guidelines for Breast Cancer update and an insightful

Full access

Julia T. van Groningen, Pieter van Hagen, Rob A.E.M. Tollenaar, Jurriaan B. Tuynman, Perla J. Marang-van de Mheen, Pascal G. Doornebosch, Pieter J. Tanis, Eelco J.R. de Graaf, and on behalf of the Dutch Colorectal Audit

evidence. 16 Long-term outcomes of both neoadjuvant and adjuvant therapy and local excision need to be confirmed by large prospective randomized trials. Currently, the Dutch national guidelines consider these treatments experimental and state that these

Full access

Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy

excision and no adjuvant therapy . J Gastrointest Surg 1999 ; 3 : 642 – 647 . 16 Guillem JG Diaz-Gonzalez JA Minsky BD . cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted . J Clin Oncol 2008 ; 26